Skip to main content
. 2016 Aug 12;7(36):58174–58180. doi: 10.18632/oncotarget.11272

Table 5. The associations between mTOR rs2295080 polymorphism and clinical characteristics of breast cancer patients.

Variables TT (%) GT (%) P OR (95% CI) GG (%) P OR (95% CI) GT + GG (%) P OR (95% CI)
Tumor size
 < 2 cm 179 (61.9) 104 (35.9) 6 (2.2) 110 (38.1)
 ≥ 2 cm 172 (63.4) 93 (34.3) 0.365 0.83 (0.55–1.25) 6 (2.3) 0.428 0.82 (0.51–1.34) 99 (36.6) 0.33 0.82 (0.56–1.21)
LN metastasis
 Negative 92 (38.9) 134 (56.8) 10 (4.3) 144 (61.1)
 Positive 259 (79.9) 63 (19.4) 0.005 0.55 (0.37–0.84) 2 (0.7) 0.001 0.65 (0.67–1.36) 219 (20.1) 0.003 0.56 (0.38–0.82)
ER
 Negative 160 (64.7) 82 (33.2) 5 (2.1) 87 (35.3)
 Positive 191 (61.0) 115 (36.7) 0.43 0.85 (0.58–1.26) 7 (2.3) 0.334 0.80 (0.50–1.26) 122 (39.0) 0.40 0.85 (0.59–1.23)
PR
 Negative 153 (60.0) 97 (38.0) 5 (2.0) 102 (40.0)
 Positive 198 (64.9) 100 (32.8) 0.909 0.98 (0.66–1.44) 7 (2.3) 0.143 0.71 (0.45–1.12) 107 (35.1) 0.48 0.89 (0.61–1.26)
Her-2
 Negative 241 (61.9) 140 (35.9) 8 (2.2) 148 (38.1)
 Positive 110 (64.3) 57 (33.3) 0.625 0.85 (0.55–1.25) 4 (2.4) 0.528 0.89 (0.61–1.37) 61 (62.7) 0.52 0.83 (0.63–1.31)

LN, Axillary lymph node; ER, Estrogen receptor; PR, Progesterone receptor; Her-2, human epidermal growth factor receptor 2.